Assenagon Asset Management S.A. Hutchmed (China) LTD Transaction History

Assenagon Asset Management S.A.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 27, 2022	SELL	$8.63 - $15.52 $4.88 Million - $8.77 Million	-565,355 Reduced 88.55%	73,091 $648,000
Q2 2022 Jul 27, 2022	BUY	$8.59 - $20.77 $4.43 Million - $10.7 Million	515,158 Added 417.85%	638,446 $8.07 Million
Q1 2022 Apr 25, 2022	SELL	$15.52 - $35.65 $499,852 - $1.15 Million	-32,207 Reduced 20.71%	123,288 $2.33 Million
Q4 2021 Feb 01, 2022	BUY	$28.89 - $35.33 $4.16 Million - $5.08 Million	143,915 Added 1242.79%	155,495 $5.46 Million
Q3 2021 Oct 19, 2021	SELL	$35.66 - $42.94 $5.94 Million - $7.16 Million	-166,675 Reduced 93.5%	11,580 $424,000
Q2 2021 Jul 15, 2021	BUY	$23.7 - $39.27 $2.2 Million - $3.65 Million	92,907 Added 108.86%	178,255 $7 Million
Q1 2021 Apr 26, 2021	BUY	$27.01 - $36.8 $2.31 Million - $3.14 Million	85,348 New	85,348 $2.41 Million
Q4 2020 Feb 01, 2021	SELL	$27.51 - $34.36 $3.78 Million - $4.72 Million	-137,476 Closed	0 $0
Q3 2020 Oct 07, 2020	BUY	$25.8 - $34.61 $1.73 Million - $2.32 Million	67,049 Added 95.2%	137,476 $4.44 Million
Q2 2020 Jul 21, 2020	BUY	$17.65 - $28.05 $1.24 Million - $1.98 Million	70,427 New	70,427 $1.94 Million

6.77M

8.2K

9.2K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.75B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.